GEFAL results support CATT, IVAN findings

SEATTLE — Like the CATT and IVAN trials, the French Evaluation Group Avastin Versus Lucentis found also that bevacizumab is non-inferior to ranibizumab, the GEFAL investigators reported here.“We found that, for our primary outcome, which is visual acuity, bevacizumab is non-inferior to ranibizumab,” study author Laurent Kodjikian, MD, PhD, said in a press briefing at the Association for Research in Vision and Ophthalmology meeting. The mean visual acuity difference between the two drugs was 1.89 letters, which is clinically meaningless, Kodjikian said.

Full Story →